What is the current valuation of the China recombinant vaccines market?

The market valuation was $27.0 Million in 2024. Read More

What is the projected market size for the China recombinant vaccines market by 2035?

The market is projected to reach $145.0 Million by 2035. Read More

What is the expected CAGR for the China recombinant vaccines market during the forecast period 2025 - 2035?

The expected CAGR is 16.51% during the forecast period. Read More

Which companies are the key players in the China recombinant vaccines market?

Key players include Pfizer, Moderna, Sanofi, GSK, Merck, Novartis, Bayer, AstraZeneca, and Boehringer Ingelheim. Read More

What are the different types of recombinant vaccines in the market?

The market segments include subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. Read More

How did the subunit recombinant vaccines perform in terms of valuation?

Subunit recombinant vaccines had a valuation range of $10.0 Million to $50.0 Million. Read More

What diseases are targeted by recombinant vaccines in the market?

Diseases targeted include pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others. Read More

What is the valuation range for hepatitis B vaccines in the market?

Hepatitis B vaccines had a valuation range of $6.0 Million to $35.0 Million. Read More

Who are the primary end-users of recombinant vaccines?

Primary end-users include hospitals & clinics, pediatrics, adults, veterinary, poultry, livestock, and others. Read More

What is the valuation range for vaccines used in pediatrics?

Vaccines used in pediatrics had a valuation range of $7.0 Million to $35.0 Million. Read More

China Recombinant Vaccines Market

ID: MRFR/Pharma/54248-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

China Recombinant Vaccines Market Research Report By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) and By End-Users (Pediatrics, Adults, Veterinary) - Growth & Industry Forecast 2025 To 2035

China Recombinant Vaccines Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type (USD Million)
  1. 4.1.1 Subunit recombinant vaccines
  2. 4.1.2 Attenuated recombinant vaccines
  3. 4.1.3 Vector recombinant vaccines
2. 4.2 Chemicals and Materials, BY Disease (USD Million)
  1. 4.2.1 Pneumococcal Disease
  2. 4.2.2 Cancer
  3. 4.2.3 Hepatitis B
  4. 4.2.4 Influenza
  5. 4.2.5 DPT
  6. 4.2.6 Others
3. 4.3 Chemicals and Materials, BY End-User (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Pediatrics
  3. 4.3.3 Adults
  4. 4.3.4 Veterinary
  5. 4.3.5 Poultry
  6. 4.3.6 Livestock
  7. 4.3.7 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Moderna (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GSK (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bayer (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Boehringer Ingelheim (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TYPE
3. 6.3 CHINA MARKET ANALYSIS BY DISEASE
4. 6.4 CHINA MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY DISEASE, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY DISEASE, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Chemicals and Materials Market Segmentation

Chemicals and Materials By Type (USD Million, 2025-2035)

Subunit recombinant vaccines
Attenuated recombinant vaccines
Vector recombinant vaccines

Chemicals and Materials By Disease (USD Million, 2025-2035)

Pneumococcal Disease
Cancer
Hepatitis B
Influenza
DPT
Others

Chemicals and Materials By End-User (USD Million, 2025-2035)

Hospitals & Clinics
Pediatrics
Adults
Veterinary
Poultry
Livestock
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓